AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PAYS

Turner Matthew Baker sold $63K of PAYS

Turner Matthew Baker (PRES., PATIENT AFFORDABILITY) sold 15,057 shares of Paysign, Inc. (PAYS) at $4.16 on 2026-02-03.

Original reporting
SEC EDGAR · Turner Matthew Baker
Published Sep 4, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PAYS
Neutral
high confidence
Mentioned
$PAYS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PAYSNeutralLow
01

Why it matters

Small insider sale, unlikely to move price materially.

02

Market read

Routine insider sale with limited trading relevance.

03

Timing

filed Sep 4 2026

Relevance 3/10Novelty 4/10Timing: filed Sep 4 2026

Background

Form 4 filing reports insider transactions for public companies.

Company-level read

Ticker impact

$PAYSNeutralHigh confidence
Context

Officer Turner Matthew Baker sold 15,057 shares for $62,637, reducing his stake to 454,943 shares.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

Sale size is modest relative to float and disclosed via Form 4, the first report of the transaction.

Key entities

  • company
    Paysign, Inc.

    Healthcare payments platform, ticker PAYS.

  • person
    Turner Matthew Baker

    President, Patient Affordability at Paysign.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PAYS insider trading history →

Related articles

$PAYSMedAI 8/10

Paysign (PAYS) Q3 2026 Earnings Call Transcript

Paysign (PAYS) reported Q3 2026 earnings, highlighting growth in its patient affordability business with revenue doubling to $16.6M YoY. Plasma revenue rose 7.5% to $13.8M. The company expects to offset a loss of 113 plasma centers with new clients. Patient affordability drove strong margins and operating leverage, while Apherion, a plasma industry software, is under regulatory review.

finance.yahoo.com
$PAYSHigh

Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8% Patient Affordability Growth Drives Revenue and Margin Expansion Raises Full Year 2026 Gross Margin, Net Income, GAAP EPS and Adju

SEC EDGAR 8-K
$PAYSHigh

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Oper

SEC EDGAR 8-K